pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·1h ago·1 min read
save

Harvard scientist George Church quits AI startup Radical, alleging partner stole his credit

Nov 7, 2026·read at Endpoints ↗Negative

George Church, a prominent Harvard researcher known for advising biotech and synthetic biology ventures, has stepped down from his role at the artificial‑intelligence startup Radical.

In a public statement, Church said the departure was driven by what he described as "sleazy" behavior by his partner, Andrew Dunn, who he claims took credit for work that was not his.

Church has previously consulted on projects ranging from de‑extinction to the development of pig organ transplants for human use, but this dispute marks a rare public conflict in his advisory activities.

The incident highlights challenges that can arise when high‑profile scientists collaborate with fast‑moving AI‑driven biotech firms.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Church quits role at AI startup Radical, claims ‘sleazy’ behavior stole credit from partner”

read at Endpoints ↗
91 words · retrieved 57m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.
topics
Rare Disease

related stories

  • Apr 28Opinion: Healthcare or health care? Help STAT decideSTAT
  • Apr 28Opinion: FDA commissioner: ‘Smarter,’ real-time clinical trials could transform drug developmentSTAT
  • Apr 28Pfizer deals extend patent life for a top-selling rare disease drugBioPharma Dive
  • Apr 28STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic accessSTAT
  • Apr 28Rocket's PRV goes for $180M; Oruka targets $500M offeringEndpoints